A detailed history of Wellington Management Group LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 1,017,647 shares of ITCI stock, worth $96.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,017,647
Previous 1,252,904 18.78%
Holding current value
$96.5 Million
Previous $85.8 Million 13.29%
% of portfolio
0.01%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $16 Million - $19 Million
-235,257 Reduced 18.78%
1,017,647 $74.4 Million
Q2 2024

Aug 13, 2024

SELL
$64.76 - $79.84 $26.5 Million - $32.7 Million
-408,966 Reduced 24.61%
1,252,904 $85.8 Million
Q1 2024

May 15, 2024

BUY
$64.37 - $75.65 $107 Million - $126 Million
1,661,870 New
1,661,870 $115 Million
Q4 2023

Feb 12, 2024

BUY
$46.37 - $73.65 $81.8 Million - $130 Million
1,763,475 New
1,763,475 $126 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $5.96 Million - $7.33 Million
114,370 Added 6.72%
1,815,954 $94.6 Million
Q2 2023

Aug 14, 2023

SELL
$54.67 - $66.44 $182 Million - $221 Million
-3,323,199 Reduced 66.14%
1,701,584 $108 Million
Q1 2023

May 12, 2023

SELL
$43.8 - $56.99 $16.9 Million - $21.9 Million
-384,902 Reduced 7.12%
5,024,783 $272 Million
Q4 2022

Feb 13, 2023

BUY
$44.07 - $54.45 $11.1 Million - $13.7 Million
250,935 Added 4.86%
5,409,685 $286 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $29.7 Million - $41.7 Million
695,392 Added 15.58%
5,158,750 $240 Million
Q2 2022

Aug 15, 2022

BUY
$43.0 - $65.64 $17.3 Million - $26.4 Million
402,198 Added 9.9%
4,463,358 $255 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $157 Million - $252 Million
4,061,160 New
4,061,160 $249 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.96B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.